SCHEMBL5043757

SCHEMBL5043757

CCC(C)NC(=O)c1cc(-c2csc(-c3cnccn3)n2)n(Cc2ccc(OC)cc2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 3/20 0.47
KLK1 P06870 1/20 0.47
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
STAT1 P42224 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
HPGD P15428 2/20 0.37
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CCR5 P51681 1/20 0.37
EIF4E P06730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045670 0.89 KLKB1 (0.51) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5047025 0.89 KLKB1 (0.49) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5044577 0.88 KLKB1 (0.46) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5046948 0.86 KLKB1 (0.50) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5049148 0.86 SREBF2 (0.44) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5043741 0.85 KLKB1 (0.50) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5039946 0.85 EIF4E (0.42) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5047028 0.83 MAPT (0.43) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5043851 0.81 SMN1; SMN2 (0.48) KLKB1KLK1RAB9ASMN1; SMN2NPC1
SCHEMBL5044779 0.80 ALDH1A1 (0.47) KLKB1RAB9ASMN1; SMN2NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885KLK1 3547/4885RAB9A 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.